Development of a psilocin immunoassay for serum and blood samples

Abstract

After the immunisation of rabbits with a psilocin-specific immunogen, polyclonal antisera were obtained. With these antisera a competitive, heterogeneous radioimmunoassay for the detection of psilocin was developed. As tracer a derivative of psilocin was synthesised, which contained a tritiated CH3 group. The antisera showed a specific reaction with psilocin. The cross-reactivity of structurally related endogenous substances like serotonin, tryptophan and tyrosine was below 0.01%. Also common drugs of abuse (Δ9-tetrahydrocannabinol, cocaine, morphine, amphetamine) showed negligible cross-reactivity (0.01–2%). Only tricyclic neuroleptics with a (dimethylamino)ethyl side-chain showed some cross-reactivity (20%). Spiked serum and blood samples were analysed with this new immunoassay and the results obtained were compared with the values measured with a validated GC-MS method.

DOI: 10.1007/s00414-004-0469-9

6 Figures and Tables

Statistics

0200400'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

130 Citations

Semantic Scholar estimates that this publication has 130 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Albers2004DevelopmentOA, title={Development of a psilocin immunoassay for serum and blood samples}, author={Christopher Albers and Helga K{\"{o}hler and Marie Lehr and Bernd Brinkmann and Justus Beike}, journal={International Journal of Legal Medicine}, year={2004}, volume={118}, pages={326-331} }